deltatrials
Completed PHASE1/PHASE2 INTERVENTIONAL 4-arm NCT02431559

Phase 1/2 Study of Motolimod, Doxorubicin, and Durvalumab in Recurrent, Platinum-Resistant Ovarian Cancer

Phase 1/2 Study of Chemoimmunotherapy With Toll-like Receptor 8 Agonist Motolimod (VTX-2337) + Anti-PD-L1 Antibody MEDI4736 in Subjects With Recurrent, Platinum-Resistant Ovarian Cancer for Whom Pegylated Liposomal Doxorubicin is Indicated

Sponsor: Cancer Research Institute, New York City

Conditions Ovarian Cancer
Interventions Durvalumab Motolimod Pegylated Liposomal Doxorubicin
Updated 14 times since 2017 Last updated: Oct 3, 2022 Started: Dec 2, 2015 Primary completion: Dec 11, 2018 Completion: Jun 10, 2021
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02431559, this PHASE1/PHASE2 trial focuses on Ovarian Cancer and remains completed. Sponsored by Cancer Research Institute, New York City, it has been updated 14 times since 2015, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Mar 2018 · 13 months · monthly snapshot~Mar 2018 – ~Jun 2018 · 3 months · monthly snapshot~Jun 2018 – ~Sep 2018 · 3 months · monthly snapshot~Sep 2018 – ~Sep 2019 · 12 months · monthly snapshot~Sep 2019 – ~Oct 2019 · 30 days · monthly snapshot~Oct 2019 – ~Nov 2019 · 31 days · monthly snapshot~Nov 2019 – ~Jan 2021 · 14 months · monthly snapshot~Jan 2021 – ~Apr 2021 · 3 months · monthly snapshot~Apr 2021 – ~Oct 2021 · 6 months · monthly snapshot~Oct 2021 – ~Nov 2022 · 13 months · monthly snapshot~Nov 2022 – ~Jul 2024 · 20 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 24 months · monthly snapshot

Change History

14 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1/PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  3. Nov 2022 — Jul 2024 [monthly]

    Completed PHASE1_PHASE2

  4. Oct 2021 — Nov 2022 [monthly]

    Completed PHASE1_PHASE2

    Status: Active Not Recruiting → Completed

  5. Apr 2021 — Oct 2021 [monthly]

    Active Not Recruiting PHASE1_PHASE2

▶ Show 9 earlier versions

  1. Jan 2021 — Apr 2021 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  2. Nov 2019 — Jan 2021 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  3. Oct 2019 — Nov 2019 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  4. Sep 2019 — Oct 2019 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  5. Sep 2018 — Sep 2019 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  6. Jun 2018 — Sep 2018 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  7. Mar 2018 — Jun 2018 [monthly]

    Active Not Recruiting PHASE1_PHASE2

    Status: Recruiting → Active Not Recruiting

  8. Feb 2017 — Mar 2018 [monthly]

    Recruiting PHASE1_PHASE2

  9. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE1_PHASE2

    First recorded

Dec 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Cancer Research Institute, New York City
  • Celgene
  • Ludwig Institute for Cancer Research
  • MedImmune LLC
Data source: Ludwig Institute for Cancer Research

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations